Dent on drug maker's image

Market watchers predict the impact of the data fabrication on domestic pharmaceutical industry is more serious than financial loss, as the Korea Food and Administration unveiled the second results of forged bioequivalence data.

Industry watchers said the government is also responsible for the fabrication as it neglected its oversight to thoroughly check whether the marketed generic drugs ar...